IBUPROFEN ORAL SUSPENSION USP
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
06-01-2021
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
IBUPROFEN
Tillgänglig från:
APOTEX INC
ATC-kod:
M01AE01
INN (International namn):
IBUPROFEN
Dos:
100MG
Läkemedelsform:
SUSPENSION
Sammansättning:
IBUPROFEN 100MG
Administreringssätt:
ORAL
Enheter i paketet:
100
Receptbelagda typ:
OTC
Terapiområde:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108883005; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2007-08-22
Produktens egenskaper
Page 1 of 30
PRODUCT MONOGRAPH
IBUPROFEN ORAL SUSPENSION
USP
100 MG/5 ML
ANALGESIC, ANTIPYRETIC AGENT – FOR CHILDREN
APOTEX INC.
150 SIGNET DRIVE
TORONTO, ONTARIO
M9L 1T9
DATE OF REVISION:
JANUARY 6, 2021
SUBMISSION CONTROL NO. 246862
Page 2 of 30
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE......................................................................................
3
CONTRAINDICATIONS
.........................................................................................................
3
WARNINGS AND
PRECAUTIONS........................................................................................
3
ADVERSE
REACTIONS.........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
9
DOSAGE AND ADMINISTRATION
.....................................................................................
10
OVERDOSAGE.....................................................................................................................
11
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................
12
STORAGE AND STABILITY
................................................................................................
14
SPECIAL HANDLING INSTRUCTIONS
..............................................................................
14
DOSAGE FORMS, COMPOSITION AND
PACKAGING.................................................... 14
PART II: SCIENTIFIC INFORMATION
...................................................................................
15
PHARMACEUTICAL INFORMATION
.................................................................................
15
CLINICAL TRIALS
.............................
Läs hela dokumentet
